Wei Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei Yan has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Wei Li
Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital Sichuan University Chengdu Sichuan China
12 shared publications Kun Zhan
Department of Dermatology and Venereology, West China Hospital, SiChuan University
4 shared publicationsYue Xiao
Department of Dermatology & Venereology, Rare Diseases Center, West China Hospital Sichuan University Chengdu China
4 shared publications- Yue Xiao
Department of Dermatology and Venereology, West China Hospital Sichuan University Chengdu China
4 shared publications Bowen Ke
Department of Anesthesiology, West China Hospital and State Key Laboratory of Biotherapy, Sichuan University, Chengdu 610041, China
3 shared publicationsHongli Wang
Department of Dermatology & Venereology, Rare Diseases Center, West China Hospital Sichuan University Chengdu China
3 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 22 (9) , e1012307
METTL1-mediated m7G modification regulates hair follicle cycle via the HOXC13/FOXN1/DSG4 axis
Rapid hair follicle cycling requires precise fate commitment and differentiation of hair follicle stem cells. While the essential role of transcription factors in establishing cell identity is well recognized, how cells control its protein synthesis to achieve tissue specificity remains unknown. RNA modifications constitute a pivotal layer of post-transcriptional regulation for protein synthesis. Among them, the N 7 -methylguanosine (m 7 G) modification has recently emerged as a critical regulator with diverse functional impacts. Here, we reveal a pivotal role of METTL1, the key enzyme for RNA m 7 G modification, in hair follicle cycle. Conditional knockout of Mettl1 in keratinocytes leads to severe hair follicle developmental dysplasia, impaired regeneration, and disrupted keratinocyte adhesion. Complementarily, keratinocyte-specific knock-in of Mettl1 accelerates hair regeneration. Mechanistically, beyond its effects on tRNAs, METTL1 deficiency destabilizes HOXC13 mRNA through internal m 7 G modification, which in turn downregulates the HOXC13/FOXN1/DSG4 signaling axis. Our findings establish METTL1-mediated internal mRNA m 7 G methylation as one of the essential regulatory layers of RNA modification in hair follicle morphogenesis and cycling, operating through the precise post-transcriptional control of a key transcriptional circuit to ensure structural integrity and timely regeneration.
- 22 September 2026
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 22 (9) , e1012307
Open AccessMETTL1-mediated m7G modification regulates hair follicle cycle via the HOXC13/FOXN1/DSG4 axis
Rapid hair follicle cycling requires precise fate commitment and differentiation of hair follicle stem cells. While the essential role of transcription factors in establishing cell identity is well recognized, how cells control its protein synthesis to achieve tissue specificity remains unknown. RNA modifications constitute a pivotal layer of post-transcriptional regulation for protein synthesis. Among them, the N 7 -methylguanosine (m 7 G) modification has recently emerged as a critical regulator with diverse functional impacts. Here, we reveal a pivotal role of METTL1, the key enzyme for RNA m 7 G modification, in hair follicle cycle. Conditional knockout of Mettl1 in keratinocytes leads to severe hair follicle developmental dysplasia, impaired regeneration, and disrupted keratinocyte adhesion. Complementarily, keratinocyte-specific knock-in of Mettl1 accelerates hair regeneration. Mechanistically, beyond its effects on tRNAs, METTL1 deficiency destabilizes HOXC13 mRNA through internal m 7 G modification, which in turn downregulates the HOXC13/FOXN1/DSG4 signaling axis. Our findings establish METTL1-mediated internal mRNA m 7 G methylation as one of the essential regulatory layers of RNA modification in hair follicle morphogenesis and cycling, operating through the precise post-transcriptional control of a key transcriptional circuit to ensure structural integrity and timely regeneration.
- Open Access
- 3 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1872304
TNF-α blockade for carbamazepine-induced drug reaction with eosinophilia and systemic symptoms
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially fatal adverse drug reaction featuring widespread eruption, fever, and multi-organ involvement. Carbamazepine is a leading causative agent in Asian populations. While systemic corticosteroids remain first-line therapy, a subset of patients exhibits corticosteroid-refractory or corticosteroid-dependent disease. Elevated tumor necrosis factor-alpha (TNF-α) levels during the acute phase provide a rationale for TNF-α blockade as an adjunctive treatment, yet clinical experience with TNF-α blockade in DRESS remains limited. Objective: To explore the potential effectiveness and safety of TNF-α inhibitors as an adjunctive treatment for DRESS. Methods: We retrospectively reviewed three consecutive inpatients diagnosed with carbamazepine-induced DRESS (RegiSCAR scores 5–9) at our dermatology department between September 2025 and March 2026. All received subcutaneous etanercept biosimilar, with individualized dosing. A systematic literature search was also performed to summarize previously published cases of DRESS treated with TNF-α inhibitors. Results: In our cohort, the three patients represented distinct phenotypes, and all had responded inadequately or transiently to corticosteroids alone. The addition of etanercept biosimilar was associated with clinical stabilization, progressive cutaneous improvement, and improvement in hepatic enzymes. Hospital stays ranged from 16 to 20 days with no etanercept-related adverse events. The literature review identified 8 previously reported DRESS cases treated with TNF-α inhibitors, the majority of which demonstrated a therapeutic response. Conclusion: Combined with previously published cases and our single-center experience, these findings support the potential benefit and an acceptable short-term safety profile of TNF-α inhibitors in this limited DRESS cohort.
- 3 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1872304
Open AccessTNF-α blockade for carbamazepine-induced drug reaction with eosinophilia and systemic symptoms
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially fatal adverse drug reaction featuring widespread eruption, fever, and multi-organ involvement. Carbamazepine is a leading causative agent in Asian populations. While systemic corticosteroids remain first-line therapy, a subset of patients exhibits corticosteroid-refractory or corticosteroid-dependent disease. Elevated tumor necrosis factor-alpha (TNF-α) levels during the acute phase provide a rationale for TNF-α blockade as an adjunctive treatment, yet clinical experience with TNF-α blockade in DRESS remains limited. Objective: To explore the potential effectiveness and safety of TNF-α inhibitors as an adjunctive treatment for DRESS. Methods: We retrospectively reviewed three consecutive inpatients diagnosed with carbamazepine-induced DRESS (RegiSCAR scores 5–9) at our dermatology department between September 2025 and March 2026. All received subcutaneous etanercept biosimilar, with individualized dosing. A systematic literature search was also performed to summarize previously published cases of DRESS treated with TNF-α inhibitors. Results: In our cohort, the three patients represented distinct phenotypes, and all had responded inadequately or transiently to corticosteroids alone. The addition of etanercept biosimilar was associated with clinical stabilization, progressive cutaneous improvement, and improvement in hepatic enzymes. Hospital stays ranged from 16 to 20 days with no etanercept-related adverse events. The literature review identified 8 previously reported DRESS cases treated with TNF-α inhibitors, the majority of which demonstrated a therapeutic response. Conclusion: Combined with previously published cases and our single-center experience, these findings support the potential benefit and an acceptable short-term safety profile of TNF-α inhibitors in this limited DRESS cohort.
- 26 May 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (8) , 1133-1141
Arthralgia and Ultrasound Characteristics of Subclinical Psoriatic Arthritis: A Cross‐Sectional Study Based on the SPAWCH Cohort
As a critical stage before psoriatic arthritis (PsA) onset, subclinical PsA provides an opportunity window for early diagnosis and intervention. This study aimed to describe the clinical and ultrasound characteristics of patients fulfilling the EULAR definition of subclinical PsA, and to explore the heterogeneity of arthralgia within this population. Patients fulfilling the EULAR definition of subclinical PsA, characterized by arthralgia and/or ultrasound evidence of synovial/entheseal inflammation without clinical synovitis, were enrolled in the Subclinical Psoriatic Arthritis Cohort of West China Hospital (SPAWCH) Cohort from January 2019 to December 2024. We collected clinical information, arthralgia features, and ultrasound findings, conducting a cross‐sectional analysis. Overall, 306 patients were included in the analysis. Among them, 84 (27.5%) had both arthralgia and ultrasound abnormalities (Group AU), 203 (66.3%) had isolated ultrasound abnormalities (Group IU), and 19 (6.2%) had isolated arthralgia (Group IA). Compared with the Group IU, patients in the Group AU were older (49.3 ± 13.7 vs. 43.5 ± 13.2 years, p = 0.001) and had a longer duration of psoriasis (17.7 ± 12.3 vs. 14.1 ± 9.8 years, p = 0.020). Additionally, the two main arthralgia types were activity‐related (60, 58.3%) and rest‐related (25, 24.3%). Rest‐related arthralgia was associated with prolonged arthralgia duration ( p = 0.041), higher morning stiffness incidence ( p = 0.031), and more prominent inflammatory characteristics ( p = 0.001) compared to activity‐related cases. In this study, ultrasound abnormalities emerged as the dominant feature in patients meeting the EULAR definition of subclinical PsA. Notably, the coexistence of arthralgia and ultrasound abnormalities was associated with a longer duration of psoriasis. While activity‐related arthralgia was the most prevalent type, rest‐related arthralgia.
- 26 May 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (8) , 1133-1141
Arthralgia and Ultrasound Characteristics of Subclinical Psoriatic Arthritis: A Cross‐Sectional Study Based on the SPAWCH Cohort
As a critical stage before psoriatic arthritis (PsA) onset, subclinical PsA provides an opportunity window for early diagnosis and intervention. This study aimed to describe the clinical and ultrasound characteristics of patients fulfilling the EULAR definition of subclinical PsA, and to explore the heterogeneity of arthralgia within this population. Patients fulfilling the EULAR definition of subclinical PsA, characterized by arthralgia and/or ultrasound evidence of synovial/entheseal inflammation without clinical synovitis, were enrolled in the Subclinical Psoriatic Arthritis Cohort of West China Hospital (SPAWCH) Cohort from January 2019 to December 2024. We collected clinical information, arthralgia features, and ultrasound findings, conducting a cross‐sectional analysis. Overall, 306 patients were included in the analysis. Among them, 84 (27.5%) had both arthralgia and ultrasound abnormalities (Group AU), 203 (66.3%) had isolated ultrasound abnormalities (Group IU), and 19 (6.2%) had isolated arthralgia (Group IA). Compared with the Group IU, patients in the Group AU were older (49.3 ± 13.7 vs. 43.5 ± 13.2 years, p = 0.001) and had a longer duration of psoriasis (17.7 ± 12.3 vs. 14.1 ± 9.8 years, p = 0.020). Additionally, the two main arthralgia types were activity‐related (60, 58.3%) and rest‐related (25, 24.3%). Rest‐related arthralgia was associated with prolonged arthralgia duration ( p = 0.041), higher morning stiffness incidence ( p = 0.031), and more prominent inflammatory characteristics ( p = 0.001) compared to activity‐related cases. In this study, ultrasound abnormalities emerged as the dominant feature in patients meeting the EULAR definition of subclinical PsA. Notably, the coexistence of arthralgia and ultrasound abnormalities was associated with a longer duration of psoriasis. While activity‐related arthralgia was the most prevalent type, rest‐related arthralgia.
- 26 March 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (4) , e70241
Immune Checkpoint Inhibitor‐Related Bullous Pemphigoid: Distinct Clinical and Immunological Profiles
Bullous pemphigoid (BP) induced by immune checkpoint inhibitors (ICI‐BP) is a rare immune‐related adverse event that affects patient prognosis and management; however, comparative data between ICI‐BP and non‐ICI BP, especially the dynamic changes of antibodies remain scarce. Therefore, we conducted this study to compare clinical presentation, immunological profile, treatment, management, and outcomes of ICI‐BP versus non‐ICI BP. This was a retrospective, single‐centre cohort study of consecutive patients between 2019 and 2025. Patients with ICI‐BP (Group A) were compared with Group B (BP with concurrent malignancy but no ICI exposure) and Group C (classic BP). There were 34, 10, and 68 patients enrolled in Groups A, B, and C, respectively (median follow‐up 24.5 months, IQR 10.8–50.0). ICI‐BP presented at a younger age (median, 59.0 years; IQR, 53.3–69.5; p < 0.001) and showed a marked male predominance (88.2%; p = 0.003). A transient, albeit non‐significant, rise in anti‐BP180 reactivity was observed during the first 2 months in ICI‐BP. Systemic glucocorticoids were required more frequently in ICI‐BP, and IL‐4 inhibitors demonstrated superior potency in accelerating BP180 antibody decline compared to non‐systematic therapy. Tumour response rates were similar between Groups A and B, as was mortality across the three groups. In conclusion, ICI‐BP differs from non‐ICI BP in clinical and immunological features and more often necessitates systemic glucocorticoid therapy, while IL‐4 inhibitors potentially expedite the reduction of anti‐BP180 antibodies in ICI‐BP patients.
- 26 March 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (4) , e70241
Immune Checkpoint Inhibitor‐Related Bullous Pemphigoid: Distinct Clinical and Immunological Profiles
Bullous pemphigoid (BP) induced by immune checkpoint inhibitors (ICI‐BP) is a rare immune‐related adverse event that affects patient prognosis and management; however, comparative data between ICI‐BP and non‐ICI BP, especially the dynamic changes of antibodies remain scarce. Therefore, we conducted this study to compare clinical presentation, immunological profile, treatment, management, and outcomes of ICI‐BP versus non‐ICI BP. This was a retrospective, single‐centre cohort study of consecutive patients between 2019 and 2025. Patients with ICI‐BP (Group A) were compared with Group B (BP with concurrent malignancy but no ICI exposure) and Group C (classic BP). There were 34, 10, and 68 patients enrolled in Groups A, B, and C, respectively (median follow‐up 24.5 months, IQR 10.8–50.0). ICI‐BP presented at a younger age (median, 59.0 years; IQR, 53.3–69.5; p < 0.001) and showed a marked male predominance (88.2%; p = 0.003). A transient, albeit non‐significant, rise in anti‐BP180 reactivity was observed during the first 2 months in ICI‐BP. Systemic glucocorticoids were required more frequently in ICI‐BP, and IL‐4 inhibitors demonstrated superior potency in accelerating BP180 antibody decline compared to non‐systematic therapy. Tumour response rates were similar between Groups A and B, as was mortality across the three groups. In conclusion, ICI‐BP differs from non‐ICI BP in clinical and immunological features and more often necessitates systemic glucocorticoid therapy, while IL‐4 inhibitors potentially expedite the reduction of anti‐BP180 antibodies in ICI‐BP patients.
- 6 March 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (7) , 1420-1430
Autoimmune Bullous Diseases Associated With Immune Checkpoint Inhibitors: An Analysis Based on a Systematic Review
Background: Autoimmune bullous diseases (AIBDs) constitute a rare yet potentially life‐threatening subset of immune‐related adverse events induced by immune checkpoint inhibitors (ICIs). However, the characteristics of ICI‐induced AIBDs (ICI‐AIBDs) and the factors influencing patient survival remain incompletely characterized. Therefore, we aimed to synthesize the available information on ICI‐AIBD patients and sought to explore factors potentially influencing the survival outcome of this population. Methods: A systematic search of 5 databases was conducted. Cox regression analysis was used to identify potential factors affecting patient survival outcomes. Results: Finally, a total of 188 studies with 319 participants were analyzed. The spectrum of AIBDs comprised bullous pemphigoid ( n = 254, 79.6%), lichen planus pemphigoides ( n = 34, 10.7%), mucous membrane pemphigoid ( n = 11, 3.4%), pemphigus group ( n = 7, 2.2%), linear IgA bullous dermatosis ( n = 5, 1.6%), primarily induced by programmed cell death protein 1 inhibitors. In the exploratory analysis, female (hazard ratio [HR], 2.35; 95% confidence interval [CI], 1.10–5.02; p = 0.020) and pemphigus group (HR, 7.09; 95% CI, 1.87–26.96; p = 0.003) were potentially associated with higher mortality, whereas topical glucocorticoid therapy was potentially protective (HR, 0.44; 95% CI, 0.21–0.93; p = 0.025). Conclusions: In conclusion, we delineate the full clinical spectrum of ICI‐AIBDs, tentatively exploring factors potentially affecting patients' survival, which provides insights for individualized therapy and may inform future clinical practice.
- 6 March 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (7) , 1420-1430
Autoimmune Bullous Diseases Associated With Immune Checkpoint Inhibitors: An Analysis Based on a Systematic Review
Background: Autoimmune bullous diseases (AIBDs) constitute a rare yet potentially life‐threatening subset of immune‐related adverse events induced by immune checkpoint inhibitors (ICIs). However, the characteristics of ICI‐induced AIBDs (ICI‐AIBDs) and the factors influencing patient survival remain incompletely characterized. Therefore, we aimed to synthesize the available information on ICI‐AIBD patients and sought to explore factors potentially influencing the survival outcome of this population. Methods: A systematic search of 5 databases was conducted. Cox regression analysis was used to identify potential factors affecting patient survival outcomes. Results: Finally, a total of 188 studies with 319 participants were analyzed. The spectrum of AIBDs comprised bullous pemphigoid ( n = 254, 79.6%), lichen planus pemphigoides ( n = 34, 10.7%), mucous membrane pemphigoid ( n = 11, 3.4%), pemphigus group ( n = 7, 2.2%), linear IgA bullous dermatosis ( n = 5, 1.6%), primarily induced by programmed cell death protein 1 inhibitors. In the exploratory analysis, female (hazard ratio [HR], 2.35; 95% confidence interval [CI], 1.10–5.02; p = 0.020) and pemphigus group (HR, 7.09; 95% CI, 1.87–26.96; p = 0.003) were potentially associated with higher mortality, whereas topical glucocorticoid therapy was potentially protective (HR, 0.44; 95% CI, 0.21–0.93; p = 0.025). Conclusions: In conclusion, we delineate the full clinical spectrum of ICI‐AIBDs, tentatively exploring factors potentially affecting patients' survival, which provides insights for individualized therapy and may inform future clinical practice.
- Open Access
- 17 August 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (10) , 1527-1535
Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort
Psoriatic arthritis (PsA) is a chronic inflammatory disease, with prevalence among psoriasis patients ranging from 6% to 42% across populations. Although targeted therapies such as adalimumab (ADA), secukinumab (SEC), and upadacitinib (UPA) have demonstrated efficacy in randomized controlled trials, real‐world head‐to‐head comparisons remain limited. This study aimed to compare the real‐world effectiveness and safety of ADA, SEC, and UPA in PsA patients. We conducted a prospective cohort study using data from the PARWCH database. PsA patients treated with ADA, SEC, or UPA were included and followed at baseline, Week 4, Week 12, and Week 24. Skin responses were evaluated using PASI75/90. Joint outcomes—including peripheral and axial arthritis—were assessed with ACR, PsARC, and ASAS criteria. Patient‐reported pain, disease activity, and HAQ scores were also recorded. Adverse events (AEs) were monitored throughout treatment. MMRM and GLMM were used to analyze continuous and binary outcomes, respectively. A total of 187 PsA patients were included (SEC: 78; ADA: 66; UPA: 43). All three agents demonstrated comparable effectiveness in improving peripheral joint symptoms (ACR20: SEC vs. ADA, Coef = −0.29, p = 0.62; UPA vs. ADA, Coef = −0.29, p = 0.66) and axial involvement (ASAS20: SEC vs. ADA, Coef = −0.04, p = 0.81; UPA vs. ADA, Coef = −1.05, p = 0.23). UPA and SEC showed significantly greater effectiveness than ADA in improving skin lesions (PASI90: SEC vs. ADA, Coef = 1.84, p = 0.006; UPA vs. ADA, Coef = 1.53, p = 0.04). However, ADA was more effective in relieving pain compared to both UPA (Coef = 2.43, p < 0.001) and SEC (Coef = 1.21, p = 0.02). Over 24 weeks, 85 AEs were reported by 48 patients, with fatigue, rash, upper respiratory tract infection, and pruritus being the most common. No serious AEs occurred. In conclusion, UPA and SEC demonstrated balanced effectiveness across skin and joint domains, while ADA offered superior pain relief. These findings support personalized treatment strategies tailored to the clinical features of PsA patients.
- 17 August 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (10) , 1527-1535
Open AccessComparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort
Psoriatic arthritis (PsA) is a chronic inflammatory disease, with prevalence among psoriasis patients ranging from 6% to 42% across populations. Although targeted therapies such as adalimumab (ADA), secukinumab (SEC), and upadacitinib (UPA) have demonstrated efficacy in randomized controlled trials, real‐world head‐to‐head comparisons remain limited. This study aimed to compare the real‐world effectiveness and safety of ADA, SEC, and UPA in PsA patients. We conducted a prospective cohort study using data from the PARWCH database. PsA patients treated with ADA, SEC, or UPA were included and followed at baseline, Week 4, Week 12, and Week 24. Skin responses were evaluated using PASI75/90. Joint outcomes—including peripheral and axial arthritis—were assessed with ACR, PsARC, and ASAS criteria. Patient‐reported pain, disease activity, and HAQ scores were also recorded. Adverse events (AEs) were monitored throughout treatment. MMRM and GLMM were used to analyze continuous and binary outcomes, respectively. A total of 187 PsA patients were included (SEC: 78; ADA: 66; UPA: 43). All three agents demonstrated comparable effectiveness in improving peripheral joint symptoms (ACR20: SEC vs. ADA, Coef = −0.29, p = 0.62; UPA vs. ADA, Coef = −0.29, p = 0.66) and axial involvement (ASAS20: SEC vs. ADA, Coef = −0.04, p = 0.81; UPA vs. ADA, Coef = −1.05, p = 0.23). UPA and SEC showed significantly greater effectiveness than ADA in improving skin lesions (PASI90: SEC vs. ADA, Coef = 1.84, p = 0.006; UPA vs. ADA, Coef = 1.53, p = 0.04). However, ADA was more effective in relieving pain compared to both UPA (Coef = 2.43, p < 0.001) and SEC (Coef = 1.21, p = 0.02). Over 24 weeks, 85 AEs were reported by 48 patients, with fatigue, rash, upper respiratory tract infection, and pruritus being the most common. No serious AEs occurred. In conclusion, UPA and SEC demonstrated balanced effectiveness across skin and joint domains, while ADA offered superior pain relief. These findings support personalized treatment strategies tailored to the clinical features of PsA patients.
- Open Access
- 26 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1565073
Demographic characteristics and disease severity associated with IgA/IgG deposition patterns in autoimmune bullous diseases: a cohort study based on a registry database
Background: Direct immunofluorescence (DIF) microscopy is the gold standard for diagnosing autoimmune bullous diseases (AIBDs), but the clinical significance of IgA and IgG co-deposition was unclear.Objective: Investigate the demographic differences and disease severity among different IgG/IgA deposition patterns in DIF.Methods: We conducted a retrospective cohort study based on a registry database that analyzed demographic data, involvement sites, and immunofluorescence patterns of patients with DIF biopsy. Patients were categorized into intercellular (group A) and basement membrane zone (group B) deposition patterns. Logistic regression models assessed associations between deposition status and demographic characteristics. Disease severity and prognosis were analyzed retrospectively through subgroup analyses.Results: In group A, female gender (OR = 1.665, P = 0.011) and stronger IgG deposition (OR = 3.881, P < 0.001) were associated with IgA and IgG co-deposition. In group B, female gender (OR = 1.382, P = 0.002), stronger IgG deposition (OR = 2.673, P < 0.001), and mucosa tissue (OR = 3.052, P < 0.001) were associated with IgA and IgG co-deposition. IgA and IgG co-deposition in group A was associated with higher Pemphigus Disease Area Index scores (P = 0.036), while in group B, it correlated with mucosal involvement (P = 0.007). No differences in the proportion of disease severity scores improvement after 6 months of standard treatment were found in both groups.Conclusions: Female gender, stronger IgG deposition, and mucosa tissue are key factors affecting IgA and IgG co-deposition in AIBD patients. For clinical correlation, patients with IgA and IgG co-deposition in pemphigus exhibit more severe disease severity compared with those with IgG deposition only, while patients with co-deposition in pemphigoid are more prone to mucosal involvement.
- 26 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1565073
Open AccessDemographic characteristics and disease severity associated with IgA/IgG deposition patterns in autoimmune bullous diseases: a cohort study based on a registry database
Background: Direct immunofluorescence (DIF) microscopy is the gold standard for diagnosing autoimmune bullous diseases (AIBDs), but the clinical significance of IgA and IgG co-deposition was unclear.Objective: Investigate the demographic differences and disease severity among different IgG/IgA deposition patterns in DIF.Methods: We conducted a retrospective cohort study based on a registry database that analyzed demographic data, involvement sites, and immunofluorescence patterns of patients with DIF biopsy. Patients were categorized into intercellular (group A) and basement membrane zone (group B) deposition patterns. Logistic regression models assessed associations between deposition status and demographic characteristics. Disease severity and prognosis were analyzed retrospectively through subgroup analyses.Results: In group A, female gender (OR = 1.665, P = 0.011) and stronger IgG deposition (OR = 3.881, P < 0.001) were associated with IgA and IgG co-deposition. In group B, female gender (OR = 1.382, P = 0.002), stronger IgG deposition (OR = 2.673, P < 0.001), and mucosa tissue (OR = 3.052, P < 0.001) were associated with IgA and IgG co-deposition. IgA and IgG co-deposition in group A was associated with higher Pemphigus Disease Area Index scores (P = 0.036), while in group B, it correlated with mucosal involvement (P = 0.007). No differences in the proportion of disease severity scores improvement after 6 months of standard treatment were found in both groups.Conclusions: Female gender, stronger IgG deposition, and mucosa tissue are key factors affecting IgA and IgG co-deposition in AIBD patients. For clinical correlation, patients with IgA and IgG co-deposition in pemphigus exhibit more severe disease severity compared with those with IgG deposition only, while patients with co-deposition in pemphigoid are more prone to mucosal involvement.
- Open Access
- 13 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1557556
Factors associated with persistent anti-desmoglein positivity after remission in pemphigus vulgaris: a prospective registry-based cohort study
Introduction: Anti-desmoglein (Dsg) antibodies are well-established markers correlated with clinical phenotype and disease severity in pemphigus vulgaris (PV). However, elevated anti-Dsg antibody levels have been observed in some patients during clinical remission (CR). This study aimed to identify clinical characteristics and risk factors in PV patients with elevated anti-Dsg antibodies after achieving CR.Methods: We conducted a cohort study based on the prospective registry database of autoimmune bullous diseases patients at West China Hospital between April 2016 and March 2022. PV patients with at least 12 months of follow-up were enrolled. The pemphigus disease area index (PDAI) and anti-Dsg antibody titers were measured at baseline and 1, 3, 6, 9, 12 months during follow-up. Univariate, multivariate analyses and receiver operating characteristics (ROC) curves were performed to identify associated factors with persistent antibody positivity and optimal cut-off values respectively. The primary outcome was the persistent positivity of antibodies against Dsg after achieving CR.Results: Among 239 PV patients enrolled in this study, 118 (49%) achieved CR. Cataracts were identified as an independent risk factor for persistent anti-Dsg1 positivity after CR. Higher baseline anti-Dsg3 antibody titers and PDAI scores were significant predictors of increased anti-Dsg3 levels post-CR, with gender also being a contributing factor. ROC analysis determined a cut-off value of 157.4 U/mL for anti-Dsg3 with 56.3% sensitivity and 82.6% specificity.Conclusion: The presence of Cataracts may indicate persistent anti-Dsg1 positivity after CR, while elevated anti-Dsg3 titers and PDAI scores at baseline may predict sustained elevated anti-Dsg3 post-CR.
- 13 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1557556
Open AccessFactors associated with persistent anti-desmoglein positivity after remission in pemphigus vulgaris: a prospective registry-based cohort study
Introduction: Anti-desmoglein (Dsg) antibodies are well-established markers correlated with clinical phenotype and disease severity in pemphigus vulgaris (PV). However, elevated anti-Dsg antibody levels have been observed in some patients during clinical remission (CR). This study aimed to identify clinical characteristics and risk factors in PV patients with elevated anti-Dsg antibodies after achieving CR.Methods: We conducted a cohort study based on the prospective registry database of autoimmune bullous diseases patients at West China Hospital between April 2016 and March 2022. PV patients with at least 12 months of follow-up were enrolled. The pemphigus disease area index (PDAI) and anti-Dsg antibody titers were measured at baseline and 1, 3, 6, 9, 12 months during follow-up. Univariate, multivariate analyses and receiver operating characteristics (ROC) curves were performed to identify associated factors with persistent antibody positivity and optimal cut-off values respectively. The primary outcome was the persistent positivity of antibodies against Dsg after achieving CR.Results: Among 239 PV patients enrolled in this study, 118 (49%) achieved CR. Cataracts were identified as an independent risk factor for persistent anti-Dsg1 positivity after CR. Higher baseline anti-Dsg3 antibody titers and PDAI scores were significant predictors of increased anti-Dsg3 levels post-CR, with gender also being a contributing factor. ROC analysis determined a cut-off value of 157.4 U/mL for anti-Dsg3 with 56.3% sensitivity and 82.6% specificity.Conclusion: The presence of Cataracts may indicate persistent anti-Dsg1 positivity after CR, while elevated anti-Dsg3 titers and PDAI scores at baseline may predict sustained elevated anti-Dsg3 post-CR.
- Top Cited PapersOpen Access
- 5 January 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (2) , 876-891
Celastrol directly targets LRP1 to inhibit fibroblast-macrophage crosstalk and ameliorates psoriasis progression
- 5 January 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (2) , 876-891
Top Cited PapersOpen AccessCelastrol directly targets LRP1 to inhibit fibroblast-macrophage crosstalk and ameliorates psoriasis progression
- Open Access
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Is Safety Profile of Apremilast in Elderly Patients Same With That in Young and Middle‐Aged Patients? A Real‐World Disproportionality Analysis of the FDA Adverse Event Reporting System
Background and Objective: Elderly individuals face heightened risks of infections, thrombosis, cardiovascular issues, and neoplasms, necessitating increased vigilance regarding adverse drug events (ADEs). The safety of apremilast in elderly patients has not been adequately explored in clinical trials. This study was to evaluate the safety profile of apremilast in young and middle‐aged patients and elderly patients separately, through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Reports in the FAERS from the third quarter of 2014 to the second quarter of 2023 were collected and analyzed. Disproportionality analyses (the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi‐item gamma Poisson shrinker (MGPS) algorithms) were employed to quantify the ADE signals of apremilast in the age groups of 18–65 years and over 65 years. Results: After data cleaning, a total of 54,926 and 14,156 ADE reports were retrieved, with 66 and 61 ADE signals identified in young and middle‐aged patients and in elderly patients, respectively. Several unexpected ADE signals not listed in the drug labeling information were detected, including pericarditis, increased cholesterol levels, liver injury, postoperative thrombosis, serum calcium, and parathyroid abnormalities. Furthermore, weight loss, psychiatric abnormalities, and infections in particular sites (ear, bursa mucosa, and central nervous system) were more significant in elderly patients. Conclusions: The study indicated several unexpected ADEs through disproportionality analysis and highlighted unique safety features in the elderly group. These findings may assist clinicians in managing psoriasis with apremilast.
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Open AccessIs Safety Profile of Apremilast in Elderly Patients Same With That in Young and Middle‐Aged Patients? A Real‐World Disproportionality Analysis of the FDA Adverse Event Reporting System
Background and Objective: Elderly individuals face heightened risks of infections, thrombosis, cardiovascular issues, and neoplasms, necessitating increased vigilance regarding adverse drug events (ADEs). The safety of apremilast in elderly patients has not been adequately explored in clinical trials. This study was to evaluate the safety profile of apremilast in young and middle‐aged patients and elderly patients separately, through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Reports in the FAERS from the third quarter of 2014 to the second quarter of 2023 were collected and analyzed. Disproportionality analyses (the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi‐item gamma Poisson shrinker (MGPS) algorithms) were employed to quantify the ADE signals of apremilast in the age groups of 18–65 years and over 65 years. Results: After data cleaning, a total of 54,926 and 14,156 ADE reports were retrieved, with 66 and 61 ADE signals identified in young and middle‐aged patients and in elderly patients, respectively. Several unexpected ADE signals not listed in the drug labeling information were detected, including pericarditis, increased cholesterol levels, liver injury, postoperative thrombosis, serum calcium, and parathyroid abnormalities. Furthermore, weight loss, psychiatric abnormalities, and infections in particular sites (ear, bursa mucosa, and central nervous system) were more significant in elderly patients. Conclusions: The study indicated several unexpected ADEs through disproportionality analysis and highlighted unique safety features in the elderly group. These findings may assist clinicians in managing psoriasis with apremilast.